Investigating how PRC1.1 affects cancer cell behavior and treatment response in neuroblastoma
Official title: Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapy
Funded at Purdue University · NIH-11192381 · Data updated 2026-11-12
This study is looking at how a specific protein complex affects neuroblastoma, a type of cancer in kids, and how changes in the cancer cells might make treatments less effective, with the goal of finding better ways to help children with high-risk neuroblastoma respond to therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | May 9, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $242,168 |
| NIH project number | 5R00CA279915-03 |
| Project ID | NIH-11192381 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with high-risk neuroblastoma who may benefit from enhanced anti-GD2 therapy.
✕Less likely to help
Patients with neuroblastoma who are not high-risk or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on understanding the role of the PRC1.1 complex in neuroblastoma, a common pediatric cancer. It aims to explore how changes in cell states influence the effectiveness of anti-GD2 therapy, which is crucial for treating high-risk neuroblastoma patients. Using advanced techniques like CRISPR-Cas9, the study will identify genetic factors that regulate GD2 expression and assess how these factors impact cancer cell differentiation and treatment resistance. By analyzing various tumor models, the research seeks to uncover new insights that could improve therapeutic strategies for affected children.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for children with neuroblastoma by enhancing the effectiveness of existing therapies.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic regulators in cancer, suggesting that this approach may yield significant advancements in treatment.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Mabe, Nathaniel — Purdue University
- Study coordinator: Mabe, Nathaniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.